Health Winners & Losers: Teva

Elsewhere, Alkermes' (ALKS Quote) shares were up 71 cents, or 6%, at $12.61 after the company announced that based on a payment by Eli Lilly, it's expanding its common stock repurchase program (previously authorized for $175 million) by $40 million and raising its 2009 fiscal year guidance.

The company now expects to earn between $10 million and $15 million, or 11 cents to 16 cents a share, vs. prior estimations of a loss of between $10 million and $15 million, or a loss of 11 cents to 16 cents a share. The company said to expect total revenue of $200 million to $225 million, vs. prior estimates of $175 million to $200 million.

Alkermes and Exelixis are both components of the Nasdaq biotechnology index, which was up 7.82, or 0.98%, at 803.08.